Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CB-011

Cell therapy (CAR-T) · Kills target cells, directed at B-cell maturation antigen (TNFRSF17) · developed by Caribou Biosciences

Phase 1 Most advanced trial
CRBU Developer
1 Registered trials

What is CB-011?

CB-011 is an allogeneic, CRISPR-edited off-the-shelf CAR-T cell therapy carrying an anti-BCMA chimeric antigen receptor. The cells recognize BCMA-expressing tumor cells and kill them through cytotoxic T-lymphocyte activity. It is studied in relapsed or refractory multiple myeloma, with cyclophosphamide and fludarabine given for lymphodepletion.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Cyclophosphamide, Fludarabine
Drug type
Cell therapy (CAR-T)
Targets
B-cell maturation antigen (TNFRSF17) (antigen)
Mechanism
Kills target cells, directed at B-cell maturation antigen (TNFRSF17)
Therapy area
Oncology
Developer
Caribou Biosciences, Inc. (CRBU)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05722418 Phase 1 Relapsed/Refractory Multiple Myeloma Recruiting CRBU

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed/Refractory Multiple Myeloma

Other drugs acting on TNFRSF17

More from Caribou Biosciences

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CRBU page.

Follow CRBU, the company behind CB-011

See CRBU's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRBU catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.